WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy biotech company. As the biopharma ...
Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...
CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today launches its first set of muscle cell disease model products designed to advance the discovery and ...
The PharmTech Group spoke with BIOVECTRA's director of Business Development, Nucleic Acid Modalities, Jessica Madigan, about the concept of flexibility in outsourcing and the 2024 BIO Convention.
OpenAI is bragging that its forthcoming models are so advanced, they may be capable of building brand-new bioweapons. In a recent blog post, the company said that even as it builds more and more ...
BioTechniques Digital Editor, Tristan Free, catches up with Guohao Dai, Associate Professor of Bioengineering at Northeastern University (MA, USA), to discuss his recent work making improvements in ...
Accurate cancer models are integral to the success of preclinical research yet have proven elusive. Mindy Goldsborough (ATCC, VA, USA) discusses the ongoing efforts to develop improved in vitro models ...
JAK2 inhibitors (JAK2i) are the standard treatment for myelofibrosis (MF), offering symptom relief and reducing spleen size. However, all FDA-approved JAK2i are type I inhibitors, which fail to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback